Elligo Health Research, a healthcare-enabling research organization, is helping Jack Nathan Health patients gain access to clinical research as a care option at its Canadian Walmart clinics. Jack Nathan Health operates physician-led medical practices that accommodate clinic appointments, lab services, physiotherapy and chiropractic services, and more.
“We take our commitment to exceptional service and care seriously,” said George Barakat, CEO at Jack Nathan Health. “Partnering with Elligo gives us the opportunity to stay informed of the newest advancements, improve our cutting-edge facilities, and continue to meet our patients’ healthcare challenges.”
This partnership expands Elligo’s Research Ready site network to include healthcare experts and their patients from across. Jack Nathan Health patients who qualify for a research study will be given the opportunity to receive treatment through Elligo’s Goes Direct approach, which connects drug development companies to a diverse pool of patients.
“To date, this is our greatest achievement in our mission to connect research to patients,” said John Potthoff, PhD, CEO of Elligo.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.